Alprostadil ﹠control

Shanghai 10th People's Hospital · FDA-approved active Small molecule

Alprostadil ﹠control is a Prostaglandin E1 analog Small molecule drug developed by Shanghai 10th People's Hospital. It is currently FDA-approved for Peripheral arterial occlusive disease, Intermittent claudication, Erectile dysfunction. Also known as: Drug: Alprostadil, lipo-alprostadil, Prostaglandin E1, Drug: normal salin.

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation.

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation. Used for Peripheral arterial occlusive disease, Intermittent claudication, Erectile dysfunction.

At a glance

Generic name	Alprostadil ﹠control
Also known as	Drug: Alprostadil, lipo-alprostadil, Prostaglandin E1, Drug: normal salin
Sponsor	Shanghai 10th People's Hospital
Drug class	Prostaglandin E1 analog
Target	Prostanoid receptors (EP receptors)
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Mechanism of action

Alprostadil binds to prostanoid receptors on vascular smooth muscle and platelets, causing relaxation of vascular smooth muscle cells and increased blood flow. It also reduces platelet activation and aggregation, improving microcirculation and tissue perfusion. These effects make it useful in conditions characterized by poor blood flow and tissue ischemia.

Approved indications

• Peripheral arterial occlusive disease
• Intermittent claudication
• Erectile dysfunction
• Diabetic angiopathy

Common side effects

• Flushing
• Headache
• Dizziness
• Hypotension
• Tachycardia
• Injection site pain

Key clinical trials

• Technology-based Distraction Techniques in Managing Children With Attention-deficit/Hyperactivity Disorder (NA)
• Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer (PHASE2)
• Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation (PHASE3)
• A Trial of Neurofeedback as an Adjunctive Treatment for Youth in Outpatient Mental Health Settings (NA)
• The Effect of a Music Intervention on Postictal Agitation in Electroconvulsive Therapy Patients (NA)
• An Intervention to Enhance Well-Being in Trauma Exposed New Mothers (NA)
• Cervical Ripening With Misoprostol vs Isosorbide Mononitrate ; A Parallel -Arm Randomized Controlled Trial (NA)
• The Effectiveness of Individualized Imagery Scripts on Sleep, Psychosis, and Suicidality Among Inpatients With Psychosis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Alprostadil ﹠control CI brief — competitive landscape report
• Alprostadil ﹠control updates RSS · CI watch RSS
• Shanghai 10th People's Hospital portfolio CI

Frequently asked questions about Alprostadil ﹠control

What is Alprostadil ﹠control?

Alprostadil ﹠control is a Prostaglandin E1 analog drug developed by Shanghai 10th People's Hospital, indicated for Peripheral arterial occlusive disease, Intermittent claudication, Erectile dysfunction.

How does Alprostadil ﹠control work?

Alprostadil is a prostaglandin E1 analog that vasodilates blood vessels and inhibits platelet aggregation.

What is Alprostadil ﹠control used for?

Alprostadil ﹠control is indicated for Peripheral arterial occlusive disease, Intermittent claudication, Erectile dysfunction, Diabetic angiopathy.

Who makes Alprostadil ﹠control?

Alprostadil ﹠control is developed and marketed by Shanghai 10th People's Hospital (see full Shanghai 10th People's Hospital pipeline at /company/shanghai-10th-people-s-hospital).

Is Alprostadil ﹠control also known as anything else?

Alprostadil ﹠control is also known as Drug: Alprostadil, lipo-alprostadil, Prostaglandin E1, Drug: normal salin.

What drug class is Alprostadil ﹠control in?

Alprostadil ﹠control belongs to the Prostaglandin E1 analog class. See all Prostaglandin E1 analog drugs at /class/prostaglandin-e1-analog.

What development phase is Alprostadil ﹠control in?

Alprostadil ﹠control is FDA-approved (marketed).

What are the side effects of Alprostadil ﹠control?

Common side effects of Alprostadil ﹠control include Flushing, Headache, Dizziness, Hypotension, Tachycardia, Injection site pain.

What does Alprostadil ﹠control target?

Alprostadil ﹠control targets Prostanoid receptors (EP receptors) and is a Prostaglandin E1 analog.

Related

• Drug class: All Prostaglandin E1 analog drugs
• Target: All drugs targeting Prostanoid receptors (EP receptors)
• Manufacturer: Shanghai 10th People's Hospital — full pipeline
• Therapeutic area: All drugs in Cardiovascular
• Indication: Drugs for Peripheral arterial occlusive disease
• Indication: Drugs for Intermittent claudication
• Indication: Drugs for Erectile dysfunction
• Also known as: Drug: Alprostadil, lipo-alprostadil, Prostaglandin E1, Drug: normal salin